Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival
Journal
Journal of Thoracic Disease
ISSN
2072-1439
2077-6624
Publisher
AME Publishing Company
Date Issued
2024
Author(s)
Martínez-Herrera, José Fabián
Sánchez Domínguez, Gisela
Juárez-Vignon Whaley, Juan J.
Carrasco-Cara Chards, Sonia
López Vrátný, Claudia
Guzmán Casta, Jordi
Riera Sala, Rodrigo F.
Alatorre-Alexander, Jorge A.
Seidman Sorsby, Alec
Cruz Zermeño, Mayte
Conde Flores, Emilio
Flores-Mariñelarena, Rodrigo R.
Sánchez-Ríos, Carla P.
Martínez-Barrera, Luis M.
Gerson-Cwilich, Raquel
Santillán-Doherty, Patricio
Jiménez López, José C.
López Hernández, William
Gutiérrez, Sebastián
Type
Resource Types::text::journal::journal article
Abstract
Background: Lung cancer represents a significant global health concern, often diagnosed in its advanced stages. The advent of massive DNA sequencing has revolutionized the landscape of cancer treatment by enabling the identification of target mutations and the development of tailored therapeutic approaches. Unfortunately, access to DNA sequencing technology remains limited in many developing countries. In this context, we emphasize the critical importance of integrating this advanced technology into healthcare systems in developing nations to improve treatment outcomes. Methods: We conducted an analysis of electronic clinical records of patients with confirmed advanced non-small cell lung cancer (NSCLC) and a verified negative status for the epidermal growth factor receptor (EGFR) mutation. These patients underwent next-generation sequencing (NGS) for molecular analysis. We performed descriptive statistical analyses for each variable and conducted both univariate and multivariate statistical analyses to assess their impact on progression-free survival (PFS) and overall survival (OS). Additionally, we classified genetic mutations as actionable or non-actionable based on the European Society for Medical Oncology Scale of Clinical Actionability of Molecular Targets (ESCAT) guidelines. © 2024 AME Publishing Company. All rights reserved.
How to cite
Martínez-Herrera, J. F., Sánchez Domínguez, G., Juárez-Vignon Whaley, J. J., Carrasco-Cara Chards, S., López Vrátný, C., Guzmán Casta, J., Riera Sala, R. F., Alatorre-Alexander, J. A., Seidman Sorsby, A., Cruz Zermeño, M., Conde Flores, E., Flores-Mariñelarena, R. R., Sánchez-Ríos, C. P., Martínez-Barrera, L. M., Gerson-Cwilich, R., Santillán-Doherty, P., Jiménez López, J. C., López Hernández, W., & Rodríguez-Cid, J. R. (2024). Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival. In Journal of Thoracic Disease (Vol. 16, Issue 1, pp. 161–174). AME Publishing Company. https://doi.org/10.21037/jtd-23-1029